|
|
Driven by our mission to discover and develop innovative medicine for improving human health, Cephalon specializes in medications to treat and manage neurological diseases, sleep disorders, cancer, pain and addiction.
|
|
05/08/2008 4:00PM
CEPH 65.04
+
2.15
Volume: 2,384,200
|
|
|
|
|
| |
|
FDA Advisory Committee meets on May 6 to consider the FENTORA(R) (fentanyl buccal tablet) [C-II] application for management of breakthrough pain in opioid-tolerant patients with chronic pain.
Read more »
|
| |
|
For the second time, Cephalon was highlighted on the FORTUNE 1000 annual ranking of America’s largest corporations.
|
| |
|
In just two decades, Cephalon has grown from a tiny biotechnology company founded by a small group of researchers to an acclaimed, international biopharmaceutical leader.
Read a message from the CEO »
|
| |
| |
See more highlights » |
|
|
|
|
Cephalon Annual Report
In 2007, Cephalon delivered exceptional earnings performance. We continued development efforts for some of our marketed products, and moved forward our exciting oncology pipeline. Learn more about our story of growth and achievement in 2007, and over the course of our remarkable 20-year history.
View the Interactive 2007 Annual Report
|
|